insights_auto
Why is VXRT up ၃.၈၀%?
Dive Deeperchevron_right
VXRT:OTCMKTS
Vaxart Inc
၀.၄၆ US$
arrow_upward
+၃.၈၀%(+၀.၀၁၇) 1D
အောက် ၁၃, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for VXRT...
Open
၀.၄၄ US$
High
၀.၄၇ US$
Low
၀.၄၂ US$
Mkt. cap
၁၁.၀၉ ကုဋေ
Avg. vol.
၂.၅၇ သိန်း
Volume
၃.၂၉ သိန်း
P/E ratio
၂.၈၀
52-wk high
၀.၈၄ US$
52-wk low
၀.၃၀ US$
EPS
၀.၁၆ US$
Beta
၁.၀၅
Shares outstanding
၂၄.၂၈ ကုဋေ
No. of employees
၆၅
Open
၀.၄၄ US$
High
၀.၄၇ US$
Low
၀.၄၂ US$
Mkt. cap
၁၁.၀၉ ကုဋေ
Avg. vol.
၂.၅၇ သိန်း
Volume
၃.၂၉ သိန်း
P/E ratio
၂.၈၀
52-wk high
၀.၈၄ US$
52-wk low
၀.၃၀ US$
EPS
၀.၁၆ US$
Beta
၁.၀၅
Shares outstanding
၂၄.၂၈ ကုဋေ
No. of employees
၆၅
News stories
From web sources and news partners
Yahoo Finance
·
ပြီးခဲ့သည့် ၅၅ မိနစ်
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
Simply Wall Street
·
ပြီးခဲ့သည့် ၄၅ မိနစ်
Does Meta (META) Have A Bigger AI Revenue Story After Muse Wonder?
HDFC Sky
·
ပြီးခဲ့သည့် ၁၇ မိနစ်
US Stocks End Mixed as Chip Selloff Hits Nasdaq
Investor's Business Daily
·
ပြီးခဲ့သည့် ၅၄ မိနစ်
Tech Futures Rise: Meta, AMD Lead 5 Buys; ASML, CPI Inflation Due
Profile
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees၆၅
Foundedမတ် ၂၀၀၄
HeadquartersSouth San Francisco, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitevaxart.com